Continued Growth in B2C Sales and Record Flower Production
Key points
- B2C revenue increased 20% quarter-on-quarter to $2.6 million, now accounting for 53% of total sales
- Total revenue reached $5.0 million, up 3% quarter-on-quarter and 10% year-on-year
- Quarterly cash receipts totalled $5.0 million, up 16% QoQ and 20% YoY
Full summary
ECS Botanics Holdings Ltd (ASX: ECS), a leading medicinal cannabis company, provided an update on its activities for the quarter ending 30 June 2025 (Q4 FY25). The company reported continued growth, with B2C revenue increasing 20% quarter-on-quarter to $2.6 million, now accounting for 53% of total sales. Total revenue reached $5.0 million, representing a 3% increase quarter-on-quarter and 10% year-on-year. Quarterly cash receipts also totalled $5.0 million, a 16% increase from the prior quarter and 20% higher than Q4 FY24. ECS marked its most successful harvest to date, yielding 10.6 tonnes of untrimmed dried flower--a 60% year-on-year increase. The company also launched Terphogz premium flower strains in June, further enhancing its branded offerings. ECS is well positioned to adapt to the evolving regulatory landscape, with a diversified product portfolio spanning fast-acting capsules, pastilles, oils, and flower. The company increased its corporate loan facility to $5.2 million, with $2.9 million remaining undrawn as at 30 June 2025, providing further flexibility to fund growth initiatives.
Guidance
The company remains confident in becoming cash flow positive in the first half of the new financial year.
Summary generated by a large language model. Please interpret with care.